Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Relapsed/Refractory Arm
Inclusion Criteria:
Exclusion Criteria:
Treatment Naïve Arm
Inclusion Criteria:
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
352 participants in 4 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal